These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study). Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Reijneveld JC; Taphoorn MJB; Coens C; Bromberg JEC; Mason WP; Hoang-Xuan K; Ryan G; Hassel MB; Enting RH; Brandes AA; Wick A; Chinot O; Reni M; Kantor G; Thiessen B; Klein M; Verger E; Borchers C; Hau P; Back M; Smits A; Golfinopoulos V; Gorlia T; Bottomley A; Stupp R; Baumert BG Lancet Oncol; 2016 Nov; 17(11):1533-1542. PubMed ID: 27686943 [TBL] [Abstract][Full Text] [Related]
6. Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. Abrunhosa-Branquinho AN; Bar-Deroma R; Collette S; Clementel E; Liu Y; Hurkmans CW; Feuvret L; Van Beek K; van den Bent M; Baumert BG; Weber DC Radiother Oncol; 2018 May; 127(2):292-298. PubMed ID: 29606522 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Tesileanu CMS; van den Bent MJ; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Sabedot TS; Hoogstrate Y; von Deimling A; de Heer I; van IJcken WFJ; Brouwer RWW; Aldape K; Jenkins RB; Dubbink HJ; Kros JM; Wesseling P; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; Noushmehr H; French PJ Neuro Oncol; 2021 Sep; 23(9):1547-1559. PubMed ID: 33914057 [TBL] [Abstract][Full Text] [Related]
9. How I treat anaplastic glioma without 1p/19q codeletion. Berghoff A; van den Bent M ESMO Open; 2019; 4(Suppl 2):e000534. PubMed ID: 31555489 [TBL] [Abstract][Full Text] [Related]
10. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Herrlinger U; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Sabel M; Hau P; Kortmann RD; Krex D; Grauer O; Goldbrunner R; Schnell O; Bähr O; Uhl M; Seidel C; Tabatabai G; Kowalski T; Ringel F; Schmidt-Graf F; Suchorska B; Brehmer S; Weyerbrock A; Renovanz M; Bullinger L; Galldiks N; Vajkoczy P; Misch M; Vatter H; Stuplich M; Schäfer N; Kebir S; Weller J; Schaub C; Stummer W; Tonn JC; Simon M; Keil VC; Nelles M; Urbach H; Coenen M; Wick W; Weller M; Fimmers R; Schmid M; Hattingen E; Pietsch T; Coch C; Glas M; Lancet; 2019 Feb; 393(10172):678-688. PubMed ID: 30782343 [TBL] [Abstract][Full Text] [Related]
11. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ; Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895 [TBL] [Abstract][Full Text] [Related]
12. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R; Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848 [TBL] [Abstract][Full Text] [Related]
13. Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study). Ahn GS; Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY Cancer Res Treat; 2022 Apr; 54(2):396-405. PubMed ID: 34237210 [TBL] [Abstract][Full Text] [Related]
14. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110 [TBL] [Abstract][Full Text] [Related]
15. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Wick W; Platten M; Meisner C; Felsberg J; Tabatabai G; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Combs SE; Vesper J; Braun C; Meixensberger J; Ketter R; Mayer-Steinacker R; Reifenberger G; Weller M; Lancet Oncol; 2012 Jul; 13(7):707-15. PubMed ID: 22578793 [TBL] [Abstract][Full Text] [Related]
16. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682 [TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Weller J; Tzaridis T; Mack F; Steinbach JP; Schlegel U; Hau P; Krex D; Grauer O; Goldbrunner R; Bähr O; Uhl M; Seidel C; Tabatabai G; Brehmer S; Bullinger L; Galldiks N; Schaub C; Kebir S; Stummer W; Simon M; Fimmers R; Coch C; Glas M; Herrlinger U; Schäfer N Lancet Oncol; 2019 Oct; 20(10):1444-1453. PubMed ID: 31488360 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504 [TBL] [Abstract][Full Text] [Related]
19. Low-grade and anaplastic oligodendroglioma. Van Den Bent MJ; Bromberg JE; Buckner J Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]